|
Patent landscape, scope, and claims: |
Scope, Claims, and U.S. Patent Landscape for US 7,528,104
US 7,528,104 claims a tightly defined erythropoietin receptor (EPO-R) activating peptide family built around a single core motif, with controlled substitutions at two positions, and with downstream claim coverage that extends to acetylated N-termini, monomers vs dimers (including homodimers), and PEGylated constructs. The patent’s enforceable scope is anchored on sequence-defined bind-and-activate activity for EPO-R and is broadened by allowable chemical modifications (acetylation, dimer linkers/spacers, PEG MW ranges and attachment patterns) while keeping the functional “target” constant (EPO-R).
What exactly does US 7,528,104 claim (independent claim architecture)?
The claim set is organized in a way that matters for both freedom-to-operate (FTO) and licensing: it starts with a single-sequence peptide claim (claim 1), then branches into (i) specific embodiments of that peptide (claims 2-14), (ii) dimers (claims 15-34), and (iii) formulations (claims 35-47). Claims 1 and 15 are the primary “sequence+function” anchors.
Core independent anchors
Claim 1 (monomer peptide, sequence-defined + functional constraint)
- Peptide length: about 17 to about 40 amino acid residues
- Core sequence (SEQ ID NO: 1):
- Substitutions:
- X0 ∈ { methionine (M), homoserine methylether (Hsm) }
- X1 ∈ { tryptophan (W), 1-naphthylalanine (1-nal), 2-naphthylalanine (2-nal) }
- Functional statement: peptide “binds to and activates the erythropoietin receptor (EPO-R)”
Claim 15 (peptide dimer, sequence-defined in at least one chain + functional constraint)
- Dimer components:
- first peptide chain
- second peptide chain
- linking moiety connecting the chains
- At least one chain includes the same “core” family motif:
- Same substitution rules for X0 and X1
- Functional statement: the dimer binds to and activates EPO-R
Implication: “binds to and activates EPO-R” is a functional limitation tied to a sequence-defined scaffold. In practice, the strongest literal coverage is for peptides that match the allowed sequences and incorporate the listed substitutions, while also being EPO-R activating.
Secondary claim structure
Monomer-specific dependent claims (2-14)
- Claim 2: N-terminus is acetylated.
- Claims 3 and 1/2 cross-coverage: explicit enumerated sequences that implement the X0/X1 options plus optional flanking glycine additions and optional end modifications. These enumerations capture concrete embodiments and can help establish literal scope even if someone argues about the generic variable definitions.
- Claims 4-6: monomer vs dimer, including homodimer.
- Claims 7-14: PEGylation:
- one or more water soluble polymers covalently bound
- polymer = PEG (claims 8, 40-47 for formulation; claim 7 is generic)
- PEG MW ranges:
- claim 9: 500 to 60,000 Da
- claim 10: < 20,000 Da
- claim 11: 20,000 to 60,000 Da
- claim 12: 20,000 to 40,000 Da
- number of PEG moieties:
- claim 13: two PEG moieties covalently bound
- claim 14: each PEG 20,000 to 30,000 Da
Dimer-specific dependent claims (17-34)
- Claims 17-20: linking moiety chemistry:
- claim 17: linking moiety formula: —NH—R3—NH—, where R3 = lower (C1-6) alkylene
- claim 18: linking moiety is lysine
- claim 19: alternative linker formula with variable spacers and amide/amine options
- claim 20: specific instance: n = 1, m = 1, X = NCO(CH2)pNR1, p = 2, R1 = H
- Claims 21-22: water soluble polymer on dimer; polymer covalently bound to linker.
- Claims 23-27: spacer moiety and PEG attachment options
- claim 24: detailed spacer moiety formula with integer ranges and conditional rule “β is 2 when γ is greater than 1.”
- claim 25: a specific spacer parameter set (α=β=γ=2; γ=1; δ=1; Y=NH)
- Claims 28-34: PEGylation details for dimers
- claim 28: PEG present
- claim 29: linear unbranched PEG 500 to 60,000 Da
- claim 30: 500 to <20,000 Da
- claim 31: 20,000 to 60,000 Da
- claim 32: 20,000 to 40,000 Da
- claim 33: two PEG moieties
- claim 34: each PEG 20,000 to 30,000 Da
Formulation claims (35-47)
- Claim 35: pharmaceutical composition comprising:
- the monomer peptide of claim 1 family
- pharmaceutically acceptable carrier
- Claims 37-39: peptide is monomer/dimer/homodimer.
- Claims 40-47: water soluble polymer covalently bound; PEG MW ranges; two PEGs each 20,000 to 30,000 Da.
How broad is the sequence scope: what variants are actually covered?
The sequence space is narrow in motif but expands via substitution sets plus explicit enumerated sequences.
Substitution-variable scope (claim 1)
Position-specific options
- Position X0: M or Hsm (2 options)
- Position X1: W, 1-nal, 2-nal (3 options)
- That yields 2 × 3 = 6 possible sequence variants for the “core” motif, before adding optional terminal or flanking residues captured in the enumerated list.
Enumerated embodiments (claim 3 and mirrored in claim 16)
The patent includes a set of 31 explicit sequences (SEQ ID NOs 2-31) under claim 3, and the same set under claim 16 for dimers. These include combinations of:
- core motif substitutions (X0 and X1)
- optional leading GGLY (adds two glycines at the N-terminus in some sequences)
- optional (AcG)GGLY... patterns that implement acetylated glycine-type N-terminal modifications
- optional (MeG) at C-terminus (methionine-based or methionine-like terminal modification as written in the claim list)
- combination of leading acetylated residues plus optional terminal (MeG) modifications
- one explicit instance variant containing Wyc (SEQ ID NO: 26 in the provided list is “WYCQPLR(MeG)” under the enumerated block), indicating the enumerated claims capture a further specific substitution beyond the generic X1 list if that is how the claim text defines it in the issued patent.
Coverage mapping table (monomer)
| Claim element |
What is allowed |
Net effect on scope |
| Core motif |
LYACHX0GPITX1VCQPLR |
Hard anchor for literal infringement analysis |
| X0 |
M or Hsm |
Limits amino acid chemistry at that position |
| X1 |
W or 1-nal or 2-nal |
Limits aromatic substitution at that position |
| Length |
about 17 to about 40 residues |
Allows flanks (but only those implemented in claim enumerations for best certainty) |
| N-terminus acetylation |
acetylated N-terminal |
Adds additional literal coverage (claim 2) |
| Enumerated sequences |
31 concrete sequences |
Converts “about” and variable terms into explicit embodiments |
How broad is the “chemistry scope” for dimers (linkers and spacers)?
The dimer branch broadens coverage beyond monomer sequences by adding structural modules, but it does so in claim-language-defined ways.
Linking moiety (claim 17 and 19-20)
Two families of linker limitations are offered:
- —NH—R3—NH— with R3 = lower (C1-6) alkylene (claim 17)
- Alternative linker formula (claim 19) with variables:
- n: 0 to 10
- m: 1 to 10
- X ∈ { O, S, N(CH2)pNR1, NCO(CH2)pNR1, CHNR1 }
- R1 ∈ { H, Boc, Cbz }
- p: 1 to 10
- claim 20 narrows to a specific case (n=1, m=1, X=NCO(CH2)pNR1, p=2, R1=H)
Claim 18 also provides an explicit linker: lysine.
Spacer moiety (claim 23-25)
Claim 24 defines spacer moiety with a conditional rule:
- formula: —NH—(CH2)α—[O—(CH2)β]γ—Oδ—(CH2)ε—Y
- ranges:
- α, β, ε independently 1 to 6
- δ is 0 or 1
- γ is 0 to 10
- constraint: β is 2 when γ > 1
- Y is NH or CO
Claim 25 sets a specific parameterization:
- α=β=2, γ=1 (as written in the provided text: “each of α, β, and γ is 2” conflicts with “Each of γ and δ is 1”; treated literally, the claim text would need to match the issued document’s exact wording. No such document text is provided here.)
Given that inconsistency, the robust take for enforcement is claim 24’s range-based spacer definition plus claim 25 as a narrower embodiment.
What is the PEGylation scope (how many variants can be captured)?
PEG coverage is a classic “scale-up and PK tuning” hook. Here it is constrained by MW ranges and by whether PEG is one or two moieties.
Monomer PEGylation (claims 7-14)
- One or more water soluble polymers covalently bound (claim 7)
- Polymer = PEG (claim 8)
- PEG MW (claim 9): 500 to 60,000 Da
- PEG MW bands:
- <20,000 (claim 10)
- 20,000 to 60,000 (claim 11)
- 20,000 to 40,000 (claim 12)
- Two PEG moieties (claim 13):
- each PEG MW: 20,000 to 30,000 (claim 14)
Dimer PEGylation (claims 21-34)
- PEG covalently bound to linker moiety (claim 22)
- PEG present with spacer (claims 23-27), PEG covalently bound to spacer (claim 27)
- Same PEG MW range logic as monomers:
- 500 to 60,000 (claim 29)
- 500 to <20,000 (claim 30)
- 20,000 to 60,000 (claim 31)
- 20,000 to 40,000 (claim 32)
- two PEG moieties each 20,000 to 30,000 (claims 33-34)
Formulation PEGylation (claims 40-47)
- Mirrors monomer PEG logic within composition claims:
- PEG MW: 500 to 60,000 (claim 42)
- 500 to <20,000 (claim 43)
- 20,000 to 60,000 (claim 44)
- 20,000 to 40,000 (claim 45)
- two PEG each 20,000 to 30,000 (claims 46-47)
What does “scope” look like in practice: infringement pathways and design-around pressure points?
Primary literal infringement pathways
A product is likely to fall within the strongest capture if it has:
- A peptide matching the core motif LYACHX0GPITX1VCQPLR with X0 ∈ {M, Hsm} and X1 ∈ {W, 1-nal, 2-nal}, and
- Binding and activation of EPO-R, and
- The structural form matches the claim layer:
- monomer (claim 1) or dimer (claim 15),
- Any PEGylation or acetylation patterns align with dependent claims (PEG MW and number constraints; N-terminal acetylation).
Pressure points for design around (based on claim language)
- Changing either X0 or X1 outside the allowed sets is the cleanest sequence-level escape.
- Moving from EPO-R activation to a different receptor mechanism can be a functional design-around if it is credible in testing, but the functional limitation is coupled to the same peptide family. For enforcement, courts often analyze whether the product meets the claimed functional limitation.
- For PEGylated products, keeping PEG MW outside the stated ranges and altering the number of PEG moieties (one vs two) can avoid dependent-claim coverage, but may not avoid the independent monomer/dimer claims if the base sequence and EPO-R activity still match.
How does this patent sit in the broader U.S. EPO-activating peptide landscape (what it likely overlaps with)?
Within the EPO-R agonist space, the landscape typically clusters into:
- EPO mimetics that are sequence-defined peptides or peptide derivatives
- PEGylated constructs to extend half-life
- Dimers or multimeric variants to increase potency or receptor engagement
US 7,528,104 is best characterized as a sequence-defined EPO-R activating peptide platform with explicit enumerated variants and with PEGylation and dimerization as controlled structural modifications. The enforced “platform” boundary is the exact core motif with allowed substitutions, not a broad “any EPO-R activating peptide” universe.
The most relevant legal overlap for competitors is likely to occur where:
- their peptides contain the same motif and substitution pattern, and/or
- their PEGylation and dimerization strategies still keep at least one chain inside the claimed family, and
- their compositions include pharmaceutically acceptable carriers with the same peptide constructs.
What should an investor or R&D lead take from claim scope for portfolio decisions?
Commercial signaling from claim drafting
- The patent’s independent claims stay on the sequence and receptor function, not on dosing or clinical endpoints.
- The dependent claims then capture practical medicinal chemistry levers (acetylation, PEG MW ranges and multiplicity, linker and spacer chemistries for dimers).
- That layering supports enforcement across multiple product forms (monomer vs dimer; free vs PEGylated; different PEG MW subranges) without abandoning the core scaffold.
Practical landscape consequence
- If a pipeline candidate matches the allowed X0/X1 substitutions and maintains EPO-R activation, it is positioned in the highest risk zone for infringement across both the peptide and composition claims.
- If it deviates at X0/X1, the remaining risk depends on whether any alternative embodiments are still captured by the enumerated sequence claims (SEQ ID NOs 2-31) and by the presence of acetylated N-termini, PEGylation, and dimer linker/spacer motifs.
Key Takeaways
- US 7,528,104 is anchored on an EPO-R activating peptide motif LYACHX0GPITX1VCQPLR with strict substitution sets (X0 = M or Hsm; X1 = W, 1-nal, or 2-nal).
- Enforceable scope extends to acetylated N-termini, PEGylated monomers, and dimer/homodimer constructs with defined linker and spacer chemistries.
- PEG coverage is constrained by MW bands and by whether one or two PEG moieties are present, with 20,000 to 30,000 Da per PEG repeatedly appearing in the narrowest dependent claims.
- The patent’s strongest infringement risk sits at the intersection of (i) sequence match, (ii) EPO-R activation, and (iii) the claimed product form (monomer vs dimer; PEGylated vs not).
FAQs
1) Does US 7,528,104 claim any EPO-R activating peptide, or only a defined family?
It claims a defined family built on the sequence LYACHX0GPITX1VCQPLR with specific X0 and X1 choices and an EPO-R binding/activation functional requirement.
2) Can a product fall under claim 15 without both dimer chains matching the core motif?
Yes. Claim 15 requires that at least one of the first or second peptide chains includes the allowed motif and substitutions.
3) Is PEG optional or required for all claim coverage?
PEG is optional. Independent coverage exists for monomer and dimer constructs; PEG enters through dependent claims and formulation claims.
4) What PEG molecular weights are explicitly within scope?
The claims repeatedly cover PEG 500 to 60,000 Da and also define narrower bands, including <20,000 Da, 20,000 to 60,000 Da, and 20,000 to 40,000 Da. For two PEG moieties, each PEG is 20,000 to 30,000 Da in the key dependent claims.
5) Does the patent cover formulations only, or also the peptide itself?
It covers both: peptide claims (monomer and dimer) and separate pharmaceutical composition claims that include the peptide plus a pharmaceutically acceptable carrier.
References
[1] U.S. Patent No. 7,528,104.
More… ↓
⤷ Start Trial
|
